LSP BioVentures

Total investments

23

Average round size

32M

Portfolio companies

22

Rounds per year

1.28

Lead investments

8

Follow on index

0.04

Exits

11

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareGeneticsManufacturingMedicalDeveloper PlatformLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

LSP BioVentures is the famous VC, which was founded in 2006. The company was established in North America in United States. The main department of described VC is located in the Cambridge.

We also calculated 10 valuable employees in our database.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Lumeon, Nouscom, Rainier Therapeutics. We can highlight the next thriving fund investment areas, such as Therapeutics, Medical. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

Opposing the other organizations, this LSP BioVentures works on 21 percentage points more the average amount of lead investments. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 44 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the LSP BioVentures, startups are often financed by Life Sciences Partners, VI Partners AG, Prolog Ventures. The meaningful sponsors for the fund in investment in the same round are VI Partners AG, Seventure Partners, PMV. In the next rounds fund is usually obtained by Life Sciences Partners, Neomed Management, Ysios Capital.

Show more

Investments analytics

Analytics

Total investments
23
Lead investments
8
Exits
11
Rounds per year
1.28
Follow on index
0.04
Investments by industry
  • Biotechnology (19)
  • Health Care (12)
  • Therapeutics (7)
  • Medical (5)
  • Pharmaceutical (5)
  • Show 15 more
Investments by region
  • Netherlands (2)
  • United States (8)
  • United Kingdom (4)
  • Switzerland (2)
  • Denmark (1)
  • Show 2 more
Peak activity year
2017
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
31M
Group Appearance index
0.87
Avg. company exit year
7
Avg. multiplicator
2.83

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Atmosoar 01 Feb 2016 Software, Information Technology, Apps, Software Engineering, Big Data, Drones, Predictive Analytics Seed 100K Hong Kong, Kowloon, China
Innovative Molecules 09 Jun 2021 Biotechnology, Health Care, Medical Early Stage Venture 23M Bayern, Munich, Germany
New Amsterdam Pharma 14 Jan 2021 Biotechnology, Life Science, Pharmaceutical Early Stage Venture 188M North Holland, The Netherlands, Netherlands
Orthonika 05 Aug 2015 Health Care, Medical Device, Medical Seed 205K England, London, United Kingdom

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.